

15th September 2011

Analyst: Steve Moore

Email: [steven.moore@gecr.co.uk](mailto:steven.moore@gecr.co.uk)

Tel: 0207 562 3370

## Port Erin Biopharma Investments\* - Admission to AIM

Today's listing on AIM of Port Erin Biopharma Investments offers an opportunity to participate in investment in the biotechnology and biopharmaceutical sector. The company's aim is to create value through investing in companies that have the potential to generate substantial revenues through the development of biopharmaceutical drugs.

Port Erin's well known Non-Executive Chairman, the entrepreneur who has had a successful fund management career, James (Jim) Mellon, has invested widely in the biopharma industry during the past two years having partly based himself in San Francisco, USA. This is an area where many industry technological developments are taking place, where many biotech companies are based and where Port Erin intends to focus its investments. Mellon, having acquired a personal portfolio of investments in the sector, is becoming well known in the US industry as an investor and is resultantly approached frequently about potential opportunities.

Port Erin intends to co-invest alongside Jim Mellon – with he recommending potential investments and the company's Chief Investment Officer, Tom Winnifrith, responsible for investment decisions. Winnifrith, the founder and CEO of PLUS-quoted Rivington Street Holdings (the ultimate owner of GE&CR), is the senior Fund Manager at t1ps Investment Management. Over both 1 and 3 years he is among the top performing 'Alpha'-rated fund manager in the UK, according to funds website *Trustnet*. Port Erin Biopharma thus marries Winnifrith's recent fund management track record with Mellon's recent sector experience. Winnifrith has not invested in biotech stocks previously and the company is to appoint an advisory panel with industry experience, with which he will consult as he considers appropriate.

The company has raised £3 million (before expenses) on its AIM admission at 10p per share, with each of the new shares coming with a warrant exercisable into a further new share at 12.5p within two years. It is envisioned that a portfolio of 20 to 25 investments will gradually be developed. This is anticipated to comprise both quoted companies - which offer the benefits of liquidity – and unquoted companies, which offer the attraction of additional capital gains upon completion of a successful IPO.

The company admits that businesses engaged in drug discovery and development are high risk in nature – e.g. risk of severe dilution in, or indeed the complete failure of, such companies as most

Key Data	
EPIC	PEBI
Share Price	10p
Total no of Shares	33,000,000
Market Cap	£3.3 million
Market	AIM
Website	<a href="http://www.porterinbiopharma.com">www.porterinbiopharma.com</a>
Sector	Investments
Contact	Tom Winnifrith (Chief Investment Officer) (01624) 676 848

drugs under development fail to reach market due to clinical trial failure. Adding to this, Port Erin Biopharma was only established on 3rd May 2011 and has yet to make any investments. However, Jim Mellon and Tom Winnifrith have attractive investment track records and are seeking to diversify some risk by restricting the amount invested in any one company to not more than 10% of Port Erin's Net Asset Value at the time of investment. They believe recent technological advances are opening up new opportunities for the development of treatments for many of the diseases that presently impact on life expectancy and quality and that they are well positioned to extract attractive investment returns from these.

*\*Port Erin Biopharma Investments is a corporate client of Rivington Street Corporate Finance, a subsidiary of Rivington Street Holdings (RSH), the ultimate owner of Growth Equities & Company Research. Rivington Street Holdings' Non-Executive Chairman, Jim Mellon, and Chief Executive, Tom Winnifrith, are directors of Port Erin Biopharma Investments and Jim Mellon and funds managed by a subsidiary of Rivington Street Holdings own shares in Port Erin Biopharma Investments as does RSH itself.*

*This research note cannot be regarded as impartial as GE&CR has been commissioned to produce it by Port Erin Biopharma Investments. It should be regarded as a marketing communication.*

*The information in this document has been obtained from sources believed to be reliable, but cannot be guaranteed. Growth Equities & Company Research is owned by T1ps.com Limited which is commissioned to produce research material under the GE&CR label. However the estimates and content of the reports are, in all cases those of T1ps.com Limited and not of the companies concerned.*

*This research report is for general guidance only and T1ps.com Limited cannot assume legal liability for any errors or omissions it might contain.*

*The value of investments can go down as well as up and you may not get back all of the money you invested; You should also be aware that the past is not necessarily a guide to the future performance. Finally, some of the shares that are written about are smaller company shares and often the market in these shares is not particularly liquid which may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. Before investing, readers should seek professional advice from a Financial Services Authorised stockbroker or financial adviser.*

*T1ps.com Limited is authorised and regulated by the Financial Services Authority (FSA Registration no. 192801) and can be contacted at 3rd Floor, 3 London Wall Buildings, London, EC2M 5SY*

*email [philip.morrish@gecr.co.uk](mailto:philip.morrish@gecr.co.uk) - fax 020 7628 3815 tel 0207 562 3362*